Aref Al-Kali, MD, Hematology, Rochester, MN, Mayo Clinic Hospital - Rochester

ArefAl-KaliMD

Hematology Rochester, MN

Hematologic Oncology

Assistant Professor, Internal Medicine, Mayo Medical School

Dr. Al-Kali is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Al-Kali's full profile

Already have an account?

Education & Training

  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterFELLOWSHIP
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterFELLOWSHIP
  • Forum Health - Western Reserve Care SystemRESIDENCY
  • Damascus University Faculty of Medicine
    Damascus University Faculty of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2017 - 2021
  • MN State Medical License
    MN State Medical License 2010 - 2021
  • TX State Medical License
    TX State Medical License 2009 - 2012
  • OK State Medical License
    OK State Medical License 2006 - 2021
  • OH State Medical License
    OH State Medical License 2002 - 2007
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Kimberly Patterson Leukemia Research award UT MD Anderson Cancer Center, 2010
  • Merit Award American Society of Hematology, 2009
  • Internal Medicine Resident Top Educators Mayo Clinic, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed with Chronic Myelomonocytic Leukemia (CMML): A Single Institution Experience  
    A Alsahlawi, H Alkhateeb, M Patnaik, K Begna, M Elliott, W Hogan, M Litzow, A Al-Kali, Clinical Lymphoma, Myeloma and Leukemia, 6/10/2014
  • Toxoplasmosis in Patients with hematologic Malignancies  
    A Chintakuntlawar, M Kidd, A Al-Kali, W Wilson, CA Thompson, Leuk Lymphoma, 5/31/2014
  • Genetic Determinants of Response and Survival in Momelotinib Treated Patients with Myelofibrosis  
    Pardanani A, Abdelrahman RA, Finke C, Lasho T, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Tefferi A, Leukemia, 1/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine
    Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
    Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
    Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis. 
    2019 ASCO Annual Meeting - 6/1/2019
  • A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Hematological Emergencies in the ICU 
    8/19/2014
  • Join now to see all

Authored Content

  • ASH 2018: The Current State of Myeloid MalignanciesDecember 2018

Press Mentions

  • Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting
    Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 MeetingDecember 12, 2017
  • Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting
    Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual MeetingMay 22, 2017
  • Ongoing AML Trials of Novel Agents Could Shift Field
    Ongoing AML Trials of Novel Agents Could Shift FieldMay 15, 2017
  • Join now to see all

Committees

  • member, NCCN MDS committee 2016 - Present

Professional Memberships

Other Languages

  • Arabic

Hospital Affiliations